Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes - PubMed (original) (raw)

Conflict of interest statement

B.L.N. is supported by an Australian National Health and Medical Research Council Postgraduate Scholarship, an Oxford Australia Clarendon Scholarship from the University of Oxford, and a University Postgraduate Award from the University of New South Wales, and has received travel support from Janssen. C.A. has nothing to disclose. V.P. has received fees for Advisory Boards, Steering Committee roles, or Scientific Presentations from Abbvie, Amgen, Astellas, Astra Zeneca, Bayer, Baxter, BMS, Boehringer Ingelheim, Chinnook, Dimerix, Durect, Eli Lilly, Gilead, GSK, Janssen, Merck, Metavant, Mitsubishi Tanabe, Mundipharma, Novartis, Novo Nordisk, Pfizer, Pharmalink, Relypsa, Retrophin, Sanofi, Servier, Vifor, Vitae, Uptodate and Tricida. G.F. has received research support from the cofunded Australian National Health and Medical Research Council and Heart Foundation Fellowship and Heart Research Australia, and has received compensation from Janssen for serving on the adjudication panel of the CANVAS Program. D.d.Z. reports serving on advisory boards and/or as a speaker for Bayer, Boehringer Ingelheim, Fresenius, Mundipharma, Mitsubishi Tanabe, serving on Steering Committees and/or as a speaker for AbbVie and Janssen, and serving on Data Safety and Monitoring Committees for Bayer. G.F. has served on Steering Committees for Janssen, has received research support from Novo Nordisk, and has served on advisory boards and as a consultant for Janssen, Novo Nordisk, Boehringer Ingelheim and Merck Sharp & Dohme. M.J. is supported by a Scientia Fellowship from the University of New South Wales (Sydney, Australia), and has received grant support from VentureWise (a wholly owned commercial subsidiary of NPS MedicineWise) to conduct a commissioned project funded by AstraZeneca (outside the submitted work). M.J.J. is supported by a Medical Research Future Fund Next Generation Clinical Researchers Programme Career Development Fellowship, is responsible for research projects that have received unrestricted funding from Gambro, Baxter, CSL, Amgen, Eli Lilly and Merck Sharpe Dohme, serves on Steering Committees sponsored by CSL and Janssen, has served on advisory boards sponsored by Akebia, AstraZeneca, Baxter, Boehringer Ingelheim, and Vifor, and has spoken at scientific meetings sponsored by Amgen, Vifor and Janssen, with any consultancy, honoraria, or travel support paid to her institution. S. Z. reports participation in advisory boards, expert committees or educational meetings on behalf of Monash University for Eli Lilly, Boehringer‐Ingelheim, Sanofi, Servier, AstraZeneca, Novo Nordisk and MSD Australia, outside the submitted work. C.P. has served on Steering Committees for Janssen, and has received honoraria for serving on advisory boards and as a speaker for AstraZeneca, Eli Lilly and Novartis. K.W.M. has received research support from Afferent, Amgen, Apple, Inc, AstraZeneca, Cardiva Medical, Inc, Daiichi, Ferring, Google (Verily), Johnson & Johnson, Luitpold, Medtronic, Merck, National Institutes of Health (NIH), Novartis, Sanofi, St. Jude and Tenax, and has served as a consultant (speaker fees for CME events only) for Abbott, Ablynx, AstraZeneca, Baim Institute, Boehringer Ingelheim, Bristol Myers Squibb, Elsevier, GlaxoSmithKline, Johnson & Johnson, MedErgy, Medscape, Mitsubishi, Myokardia, NIH, Novartis, Novo Nordisk, Portola, Radiometer, Regeneron, SmartMedics, Springer Publishing and UCSF. B.N. is supported by an Australian National Health and Medical Research Council Principal Research Fellowship, holds a research grant for this study and has served on Steering Committees for Janssen, and has served on advisory boards and as a consultant for Janssen, Mitsubishi Tanabe Pharma Corp., Merk Sharpe Dohme and Servier, with all fees paid to his institution. H.J.L.H. has served as a consultant for Abbvie, AstraZeneca, Boehringer Ingelheim, Chinook, Dimerix, Janssen, Merck, MundiPharma and Mitsubishi‐Tanabe, Retrophin, and has received grant support from Abbvie, AstraZeneca, Boehringer Ingelheim and Janssen.